Progression free survival is superior with alemtuzumab vs chlorambucil as front-line therapy for patients with B-cell chronic lymphocytic leukemia

被引：0
|
作者：
Hillmen, P.
Skotnicki, A.
Robak, T.
Jaksic, B.
Sirard, C.
Mayer, J.
机构：
[1] Leeds Gen Infirm, Leeds, W Yorkshire, England
[2] Jagiellonian Univ, Coll Med, Krakow, Poland
[3] Kopernik Mem Hosp, Lodz, Poland
[4] Univ Zagreb, Clin Hosp Merkur, Zagreb, Croatia
[5] GENZYME, Cambridge, MA USA
[6] Univ Hosp Brno, Brno, Czech Republic
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2007年 / 92卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0127
引用
收藏
页码：45 / 46
页数：2
相关论文
共 50 条
  • [21] Alemtuzumab therapy for severe autoimmune hemolysis in a patient with B-cell chronic lymphocytic leukemia
    Jeanette Lundin
    Claes Karlsson
    Fredrik Celsing
    Medical Oncology, 2006, 23 (1) : 137 - 139
  • [22] Alemtuzumab therapy for severe autoimmune hemolysis in a patient with B-cell chronic lymphocytic leukemia
    Lundin, J
    Karlsson, C
    Celsing, F
    MEDICAL ONCOLOGY, 2006, 23 (01) : 137 - 139
  • [23] Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification
    Laurenti, Luca
    Innocenti, Idanna
    Autore, Francesco
    Ciolli, Stefania
    Mauro, Francesca Romana
    Mannina, Donato
    Del Poeta, Giovanni
    D'Arena, Giovanni
    Massaia, Massimo
    Coscia, Marta
    Molica, Stefano
    Pozzato, Gabriele
    Efremov, Dimitar G.
    Vannata, Barbara
    Marasca, Roberto
    Galieni, Pietro
    Cuneo, Antonio
    Orlando, Sonia
    Piciocchi, Alfonso
    Boncompagni, Riccardo
    Vincelli, Donatella
    Liberati, Anna Marina
    Russo, Filomena
    Foa, Robin
    HAEMATOLOGICA, 2017, 102 (09) : E352 - E355
  • [24] EFFICACY AND SAFETY OF CHLORAMBUCIL PLUS RITUXIMAB AS FRONT-LINE THERAPY IN ELDERLY AND/OR UNFIT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA. A GIMEMA RETROSPECTIVE STUDY
    Laurenti, L.
    Autore, F.
    Innocenti, I.
    Vannata, B.
    Ciolli, S.
    Mauro, F. R.
    Mannina, D.
    Del Poeta, G.
    D'Arena, G.
    Massaia, M.
    Coscia, M.
    Molica, S.
    Pozzato, G.
    Marasca, R.
    Galieni, P.
    Cuneo, A.
    Orlando, S.
    Piciocchi, A.
    Boncompagni, R.
    Vincelli, D.
    Liberati, A. M.
    Russo, F.
    Foa, R.
    HAEMATOLOGICA, 2015, 100 : 134 - 134
  • [25] Incidence of genomic aberrations and associated efficacy from a phase III study comparing alemtuzumab (CAMPATH®, MABCAMPATH®) vs chlorambucil as first line therapy for B-cell chronic lymphocytic leukemia (BCLL).
    Robak, Tadeusz
    Dmoszynska, Anna
    Fetni, Raouf
    Wang, Ying
    Belkacz, Malika
    Sirard, Cynthia
    Goldberg, Mark
    Skotnicki, Aleksander
    Mayer, Jiri
    Hillmen, Peter
    BLOOD, 2006, 108 (11) : 593A - 593A
  • [26] Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia
    Robak, T
    Blonski, JZ
    Kasznicki, M
    Góra-Tybor, J
    Dwilewicz-Trojaczek, J
    Boguradzki, P
    Konopka, L
    Ceglarek, B
    Sulek, J
    Kuliczkowski, K
    Wolowiec, D
    Stella-Holowiecka, B
    Skotnicki, AB
    Nowak, W
    Moskwa-Sroka, B
    Dmoszynska, A
    Calbecka, M
    LEUKEMIA, 2001, 15 (10) : 1510 - 1516
  • [27] Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia
    T Robak
    JZ Błoński
    M Kasznicki
    J Góra-Tybor
    J Dwilewicz-Trojaczek
    P Boguradzki
    L Konopka
    B Ceglarek
    J Sułek
    K Kuliczkowski
    D Wołowiec
    B Stella-Hołowiecka
    AB Skotnicki
    W Nowak
    B Moskwa-Sroka
    A Dmoszyńska
    M Calbecka
    Leukemia, 2001, 15 : 1510 - 1516
  • [28] Rituximab therapy of patients with B-cell chronic lymphocytic leukemia
    Huhn, D
    von Schilling, C
    Wilhelm, M
    Ho, AD
    Hallek, M
    Kuse, R
    Knauf, W
    Riedel, U
    Hinke, A
    Srock, S
    Serke, S
    Peschel, C
    Emmerich, B
    BLOOD, 2001, 98 (05) : 1326 - 1331
  • [29] Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival
    Moreton, P
    Kennedy, B
    Lucas, G
    Leach, M
    Rassam, SMB
    Haynes, A
    Tighe, L
    Oscier, D
    Fegan, C
    Rawstron, A
    Hillmen, P
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (13) : 2971 - 2979
  • [30] Management guidelines for use of alemtuzumab in B-Cell chronic lymphocytic leukemia
    Keating, M
    Coutré, S
    Rai, K
    Österborg, A
    Faderl, S
    Kennedy, B
    Kipps, T
    Bodey, G
    Byrd, JC
    Rosen, S
    Dearden, C
    Dyer, MJS
    Hillmen, P
    CLINICAL LYMPHOMA, 2004, 4 (04): : 220 - 227
12345